Pharmaceutical giant GSK has announced successful outcomes from its Phase III B-Well 1 and B-Well 2 clinical trials, establishing a foundation for the global regulatory submission of bepirovirsen. This investigational antisense oligonucleotide (ASO) aims to transform the treatment landscape for chronic hepatitis B (CHB).
Key trial results and clinical insights:
-
Functional cure achievement: Across two studies involving over 1,800 participants, bepirovirsen met its primary endpoint. The drug, when added to the current standard of care, demonstrated a statistically significant higher rate of “functional cure” compared to standard treatment alone.
-
Triple-action mechanism: The therapy works by inhibiting viral DNA replication, suppressing hepatitis B surface antigen (HBsAg) levels, and boosting the patient’s immune response to foster a durable recovery.
-
Target population efficacy: A notably stronger therapeutic effect was observed in patients entering the trial with lower baseline surface antigen levels ( 1000 IU/ml).
-
Strategic shift: Approval of this drug would introduce the first finite six-month treatment regimen for CHB. This contrasts with existing nucleoside/nucleotide analogue therapies, which typically require lifelong administration.
GSK plans to initiate global regulatory filings in the first quarter of 2026. Bepirovirsen has already been granted expedited designations, including Fast Track from the US FDA, Breakthrough Therapy in China, and SENKU in Japan.